Yuangang Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuangang Lu has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
Xinying Li
Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042, China
18 shared publicationsJunbo Zhang
Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China
10 shared publicationsLiuchang Tan
Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China
9 shared publicationsYuanyuan Wang
Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China
8 shared publicationsChuanqi Zhao
Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China
7 shared publicationsHuiling Kou
Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China
7 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 59, 105479
Efficacy of PDD-guided tumor excision combined with photodynamic therapy in high-risk basal cell carcinoma
- 16 April 2026
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 59, 105479
Open AccessEfficacy of PDD-guided tumor excision combined with photodynamic therapy in high-risk basal cell carcinoma
- 28 March 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 815, 153686
Circ-ZBTB38 as an oncogenic circular RNA: Mechanisms in disrupting RalGAP complexes and its clinical value in melanoma
- 28 March 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 815, 153686
Circ-ZBTB38 as an oncogenic circular RNA: Mechanisms in disrupting RalGAP complexes and its clinical value in melanoma
- Open Access
- 23 March 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103056
Ultrasmall Prussian blue–integrated cryogel for enhanced ROS scavenging and immunomodulation via cGAS–STING inhibition in wound healing
- 23 March 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103056
Open AccessUltrasmall Prussian blue–integrated cryogel for enhanced ROS scavenging and immunomodulation via cGAS–STING inhibition in wound healing
- 19 January 2026
- Published by Springer Nature in International Journal of Biometeorology
- Vol. 70 (2) , 30
Non-optimal apparent temperatures can increase the risk of acne: a multi-center time-series study
As extreme temperature events increase globally, the influences of non-optimal temperature on health outcomes are of increasing concern. However, whether there is a correlation between non-optimal apparent temperature (AT) and acne is unknown. To illustrate the association between non-optimal AT and acne, data of daily acne outpatient visits, meteorological factors, and air pollutants from 2015 to 2019 in Chongqing, China were obtained. A multi-center study using distributed lag non-linear model (DLNM) was employed to explore the possible association between short-term non-optimal AT and outpatient visits for acne. Stratified analyses by age and gender were carried out to verify vulnerable populations. Results showed that both cold and hot AT were significantly associated with acne. The significant single-lag effects of cold AT lasted from lag0 to lag3, and cumulative-lag effects lasted from lag00 to lag07, with the highest relative risk of 1.09 (95%CI: 1.03–1.17) on lag0, and 1.34 (95%CI: 1.17–1.53) on lag07, respectively. In term of hot AT, the significant single-lag effects were observed from lag0 to lag3 with cumulative-lag effects from lag00 to lag07, with peak relative risk of 1.08 (95%CI: 1.02–1.14) on lag0 and 1.17 (95%CI: 1.08–1.27) on lag03, respectively. Stratified analyses showed that young patients (< 25 years old) and males were more susceptible to non-optimal AT. We provide the first evidence that non-optimal AT can increase the risk of acne, particularly for young people and males. Our findings add new sights regarding the potential adverse effects of non-optimal temperature on skin diseases especially acne.
- 19 January 2026
- Published by Springer Nature in International Journal of Biometeorology
- Vol. 70 (2) , 30
Non-optimal apparent temperatures can increase the risk of acne: a multi-center time-series study
As extreme temperature events increase globally, the influences of non-optimal temperature on health outcomes are of increasing concern. However, whether there is a correlation between non-optimal apparent temperature (AT) and acne is unknown. To illustrate the association between non-optimal AT and acne, data of daily acne outpatient visits, meteorological factors, and air pollutants from 2015 to 2019 in Chongqing, China were obtained. A multi-center study using distributed lag non-linear model (DLNM) was employed to explore the possible association between short-term non-optimal AT and outpatient visits for acne. Stratified analyses by age and gender were carried out to verify vulnerable populations. Results showed that both cold and hot AT were significantly associated with acne. The significant single-lag effects of cold AT lasted from lag0 to lag3, and cumulative-lag effects lasted from lag00 to lag07, with the highest relative risk of 1.09 (95%CI: 1.03–1.17) on lag0, and 1.34 (95%CI: 1.17–1.53) on lag07, respectively. In term of hot AT, the significant single-lag effects were observed from lag0 to lag3 with cumulative-lag effects from lag00 to lag07, with peak relative risk of 1.08 (95%CI: 1.02–1.14) on lag0 and 1.17 (95%CI: 1.08–1.27) on lag03, respectively. Stratified analyses showed that young patients (< 25 years old) and males were more susceptible to non-optimal AT. We provide the first evidence that non-optimal AT can increase the risk of acne, particularly for young people and males. Our findings add new sights regarding the potential adverse effects of non-optimal temperature on skin diseases especially acne.
- Open Access
- 8 January 2026
- Published by Elsevier in Materials & Design
- Vol. 262
Bimetallic ions assist honokiol in promoting skin wound healing
- 8 January 2026
- Published by Elsevier in Materials & Design
- Vol. 262
Open AccessBimetallic ions assist honokiol in promoting skin wound healing
- Open Access
- 8 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e10545
Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring
Current clinical treatments for skin scars primarily reduce vascular density in situ. But, outcomes remain unsatisfactory due to limited understanding of scar vascular structure, endothelial cell (EC) heterogeneity, and functional changes. Through dermatoscopy, scanning electron microscopy, and immunofluorescence staining, our study revealed substantial vascular remodeling in scars, including increased neovascularization density, branching complexity, and incomplete vascular wall coverage. Single‐cell sequencing constructed an EC atlas of scar patients, identifying upregulated ATP synthesis, decomposition, and oxidative phosphorylation in scar ECs—characteristics resembling tumor vasculature. Notably, a subset of ECs with high neuropilin‐1 (NRP1) expression exhibited mesenchymal characteristics. In vitro experiments demonstrated that NRP1 knockdown blocked the transforming growth factor‐beta (TGF‐β)/SMAD family member 2 (SMAD2) signaling pathway and mitigated endothelial‐to‐mesenchymal transition (EndMT). Importantly, NRP1 inhibition reduced EndMT, restored normal vascular function and structure, and prevented scar formation in mice. Based on these findings, a functional hydrogel spray was developed using an NRP1‐targeting peptide, effectively preventing scar formation by promoting vascular normalization.
- 8 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e10545
Open AccessTargeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring
Current clinical treatments for skin scars primarily reduce vascular density in situ. But, outcomes remain unsatisfactory due to limited understanding of scar vascular structure, endothelial cell (EC) heterogeneity, and functional changes. Through dermatoscopy, scanning electron microscopy, and immunofluorescence staining, our study revealed substantial vascular remodeling in scars, including increased neovascularization density, branching complexity, and incomplete vascular wall coverage. Single‐cell sequencing constructed an EC atlas of scar patients, identifying upregulated ATP synthesis, decomposition, and oxidative phosphorylation in scar ECs—characteristics resembling tumor vasculature. Notably, a subset of ECs with high neuropilin‐1 (NRP1) expression exhibited mesenchymal characteristics. In vitro experiments demonstrated that NRP1 knockdown blocked the transforming growth factor‐beta (TGF‐β)/SMAD family member 2 (SMAD2) signaling pathway and mitigated endothelial‐to‐mesenchymal transition (EndMT). Importantly, NRP1 inhibition reduced EndMT, restored normal vascular function and structure, and prevented scar formation in mice. Based on these findings, a functional hydrogel spray was developed using an NRP1‐targeting peptide, effectively preventing scar formation by promoting vascular normalization.
- 14 November 2025
- Published by Springer Nature in Human Cell
- Vol. 39 (1) , 9
Establishment and characterization of a novel imatinib-resistant dermatofibrosarcoma protuberans cell line, DFSP-DPH1
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive cutaneous sarcoma characterized by high recurrence rates and the development of resistance to imatinib. The scarcity of preclinical models hinders research into DFSP pathogenesis and the development of novel therapeutic strategies. In this study, we established and characterized a novel DFSP cell line, designated DFSP-DPH1, derived from a 47-year-old male patient with an abdominal tumor. Comprehensive characterization confirmed that DFSP-DPH1 retains key features of the original tumor, including the fibroblast-like spindle morphology and expression of diagnostic markers CD34 and vimentin, with absence of factor XIIIa. Short tandem repeat profiling confirmed the cell line's origin and excluded cross-contamination. Sanger sequencing revealed a COL1A1 exon 46-PDGFB exon 2 fusion transcript, a breakpoint not previously reported in established DFSP cell lines. Functionally, DFSP-DPH1 exhibits robust proliferative capacity, forms three-dimensional spheroids under anchorage-independent conditions, and demonstrates significant migratory and invasive capabilities. Drug sensitivity screening of a panel of 48 PDGFR inhibitors confirmed its resistance to imatinib and identified several compounds with superior efficacy compared to imatinib. Transcriptomic analysis confirmed the dominance of the COL1A1::PDGFB fusion transcript and revealed enrichment of pathways related to cancer, viral infection, and neuroactive ligand–receptor interaction. This novel imatinib-resistant DFSP cell line, DFSP-DPH1 provides a valuable preclinical model for investigating the molecular mechanisms underlying DFSP pathogenesis, drug resistance, and tumor progression, and for developing and evaluating novel therapeutic strategies.
- 14 November 2025
- Published by Springer Nature in Human Cell
- Vol. 39 (1) , 9
Establishment and characterization of a novel imatinib-resistant dermatofibrosarcoma protuberans cell line, DFSP-DPH1
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive cutaneous sarcoma characterized by high recurrence rates and the development of resistance to imatinib. The scarcity of preclinical models hinders research into DFSP pathogenesis and the development of novel therapeutic strategies. In this study, we established and characterized a novel DFSP cell line, designated DFSP-DPH1, derived from a 47-year-old male patient with an abdominal tumor. Comprehensive characterization confirmed that DFSP-DPH1 retains key features of the original tumor, including the fibroblast-like spindle morphology and expression of diagnostic markers CD34 and vimentin, with absence of factor XIIIa. Short tandem repeat profiling confirmed the cell line's origin and excluded cross-contamination. Sanger sequencing revealed a COL1A1 exon 46-PDGFB exon 2 fusion transcript, a breakpoint not previously reported in established DFSP cell lines. Functionally, DFSP-DPH1 exhibits robust proliferative capacity, forms three-dimensional spheroids under anchorage-independent conditions, and demonstrates significant migratory and invasive capabilities. Drug sensitivity screening of a panel of 48 PDGFR inhibitors confirmed its resistance to imatinib and identified several compounds with superior efficacy compared to imatinib. Transcriptomic analysis confirmed the dominance of the COL1A1::PDGFB fusion transcript and revealed enrichment of pathways related to cancer, viral infection, and neuroactive ligand–receptor interaction. This novel imatinib-resistant DFSP cell line, DFSP-DPH1 provides a valuable preclinical model for investigating the molecular mechanisms underlying DFSP pathogenesis, drug resistance, and tumor progression, and for developing and evaluating novel therapeutic strategies.
- 23 September 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 452 (2) , 114770
Optogenetic engineered macrophages for light-induced M1 polarization and enhanced chemo-immunotherapy in melanoma models
- 23 September 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 452 (2) , 114770
Optogenetic engineered macrophages for light-induced M1 polarization and enhanced chemo-immunotherapy in melanoma models
- 22 September 2025
- Published by Elsevier in Tissue and Cell
- Vol. 98, 103141
Formononetin enhances angiogenesis in diabetic wounds by inhibiting ferroptosis through suppression of mtROS-mediated xCT/GPX4 upregulation
- 22 September 2025
- Published by Elsevier in Tissue and Cell
- Vol. 98, 103141
Formononetin enhances angiogenesis in diabetic wounds by inhibiting ferroptosis through suppression of mtROS-mediated xCT/GPX4 upregulation